- Home
- ARKO vs CTNM Comparison
ARKO vs CTNM Comparison
Compare ARKO & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ARKO | CTNM |
|---|---|---|
| Founded | 1970 | 2009 |
| Country | United States | United States |
| Employees | N/A | 41 |
| Industry | Oil Refining/Marketing | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.7M | 575.3M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | ARKO | CTNM |
|---|---|---|
| Price | $6.41 | $15.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $7.50 | ★ $18.60 |
| AVG Volume (30 Days) | ★ 498.5K | 281.1K |
| Earning Date | 02-27-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $7,887,822,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $58.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.51 | $3.35 |
| 52 Week High | $7.84 | $15.92 |
Technical Indicators
Market Signals| Indicator | ARKO | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 71.77 | 65.79 |
| Support Level | $5.03 | $13.86 |
| Resistance Level | $6.71 | $15.47 |
| Average True Range (ATR) | 0.24 | 1.15 |
| MACD | 0.09 | 0.13 |
| Stochastic Oscillator | 77.61 | 78.93 |
Price Performance
Historical ComparisonAbout ARKO ARKO Corp.
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.